Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity

Growth Factors

Volumn 27, Issue 6, 2009, Pages 377-383

  Gong, Chang Yang ^a   Shi, Shuai ^a   Peng, Xin Yun ^b   Kan, Bing ^a   Yang, Li ^a   Huang, Mei Juan ^a   Luo, Feng ^a   Zhao, Xia ^a   Wei, Yu Quan ^a   Qian, Zhi Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN NORMAL UNIVERSITY   (China)

Author keywords

Basic fibroblast growth factor (bFGF); Biodegradable; Controlled release; Thermosensitive hydrogel; Vaccine.

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; MACROGOL; MACROGOL POLYCARPROLACTONE MACROGOL COPOLYMER; POLYCAPROLACTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BIODEGRADABILITY; BODY TEMPERATURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENVIRONMENTAL TEMPERATURE; FEMALE; HEAT SENSITIVITY; HUMORAL IMMUNITY; HYDROGEL; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ANIMALS; ANTIBODIES; ANTIGENS; BIOCOMPATIBLE MATERIALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HOT TEMPERATURE; HUMANS; HYDROGEL; IMMUNITY, HUMORAL; INJECTIONS; L CELLS (CELL LINE); MICE; MICE, INBRED BALB C; POLYESTERS; POLYETHYLENE GLYCOLS; VACCINES;

EID: 70450207980     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977190903159938     Document Type: Article

References (27)

1. Bowersock TL, Martin S. 1999. Vaccine delivery to animals. Adv Drug Deliv Rev 38(2):167-194.
2. Coeshott CM, Smithson SL, Verderber E, Samaniego A, Blonder JM, Rosenthal GJ, Westerink MAJ. 2004. Pluronic @F127-based systemic vaccine delivery systems. Vaccine 22(19):2396-2405.
3. Gong C, Qian Z, Liu C, Huang M, Gu Y, Wen Y, Kan B, Wang K, Dai M, Li X, Gou M, Tu M, Wei Y. 2007. A thermosensitive hydrogel based on biodegradable amphiphilic poly(ethylene glycol)-polycaprolactone-poly(ethylene glycol) block copolymers. Smart Mater Struct 16(3):927-933. (Pubitemid 46804865)
4. Gong C, Shi S, Dong P, Kan B, Gou M, Wang X, Li X, Luo F, Zhao X, Wei Y, Qian Z. 2009a. Synthesis and characterization of PEG-PCL-PEG thermosensitive hydrogel. Int J Pharm 365(1-2):89-99.
5. Gong C, Shi S, Dong P, Zheng X, Fu S, Guo G, Yang J, Wei Y, Qian Z. 2009b. In vitro drug release behavior from a novel thermosensitive composite hydrogel based on Pluronic f127 and poly(ethylene glycol)-poly(epsilon- caprolactone)-poly(ethylene glycol) copolymer. BMC Biotechnol 9(1):8.
6. GouM,HuangM,Qian Z,Yang L, DaiM,Li X,Wang K,WenY,Li J, Zhao X, Wei Y. 2007. Preparation of anionic poly(1-caprolactone)- poly(ethylene glycol)-poly(1-caprolactone) copolymeric nanoparticles as basic protein antigen carrier. Growth Factors 25(3):202-208.
7. Gou M, Dai M, Gu Y, Li X,Wen Y, Yang L,Wang K,Wei Y, Qian Z. 2008a. BFGF loaded biodegradable PCL-PEG-PCL copolymeric nanoparticles: Preparation, in vitro release and immunogenicity study. J Nanosci Nanotechnol 8:1-5.
8. Gou M, Dai M, Li X, Yang L, Huang M, Wang Y, Kan B, Lu Y, Wei Y, Qian Z. 2008b. Preparation of mannan modified anionic PCL-PEG-PCL nanoparticles at one-step for bFGF antigen delivery to improve humoral immunity. Colloids Surf B Biointerfaces 64(1):135-139.
9. Gupta RK. 1998. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32(3):155-172.
10. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. 1993. Adjuvants - A balance between toxicity and adjuvanticity. Vaccine 11(3):293-306.
11. Hanes J, Cleland JL, Langer R. 1997. New advances in microsphere-based single-dose vaccines. Adv Drug Deliv Rev 28(1):97-119.
12. Julie Westerink MA, Louise Smithson S, Srivastava N, Blonder J, Coeshott C, Rosenthal GJ. 2001. ProJuvantTM (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 20(5-6):711-723.
13. Kang ML, Jiang H-L, Kang SG, Guo DD, Lee DY, Cho C-S, Yoo HS. 2007. Pluronic@F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine 25(23):4602-4610.
14. Liu MA. 1999. Topic in review: Vaccines in the 21st century.West J Med 171(5-6):319-322.
15. Liu J-Y,Wei Y-Q, Yang L, Zhao X, Tian L, Hou J-M, Niu T, Liu F, Jiang Y, Hu B,Wu Y, Su J-M, Lou Y-Y, He Q-M,Wen Y-J, Yang J-L, Kan B, Mao Y-Q, Luo F, Peng F. 2003. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102(5):1815-1823.
16. Lu Y, Wei Y-Q, Tian L, Zhao X, Yang L, Hu B, Kan B, Wen Y-J, Liu F, Deng H-X, Li J, Mao Y-Q, Lei S, Huang M-J, Peng F, Jiang Y, Zhou H, Zhou L-Q, Luo F. 2003. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 170(6):3162-3170.
17. O'Hagan DT, Rappuoli R. 2004. The safety of vaccines. Drug Discov Today 9(19):846-854.
18. O'Hagan DT, Rappuoli R. 2006. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev 58(1):29-51.
19. O'Hagan DT, MacKichan ML, Singh M. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18(3):69-85.
20. Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE, Fortier AH. 2000. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 19(9-10):1294-1303.
21. Poland GA, Murray D, Bonilla-Guerrero R. 2002. Science, medicine, and the future: New vaccine development. BMJ 324(7349):1315-1319.
22. Singh M, O'Hagan DT. 1999. Advances in vaccine adjuvants. Nat Biotech 17(11):1075-1081.
23. Singh M, O'Hagan DT. 2002. Recent advances in vaccine adjuvants. Pharm Res 19(6):715-728.
24. Wang L-L, Li J-J, Zheng Z-B, Liu H-Y, Du G-J, Li S. 2004. Antitumor activities of a novel indolin-2-ketone compound, Z24: More potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells. Eur J Pharmacol 502(1-2): 1-10.
25. Wei Y-Q, Wang Q-R, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu C-J, Huang M-J, Lou Y-Y, Xiao F, He Q-M, Shu J-M, Xie X-J, Mao Y-Q, Lei S, Luo F, Zhou L-Q, Liu C-E, Zhou H, Jiang Y. 2000. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6(10):1160-1166.
26. Wei Y-Q, Huang M-J, Yang L, Zhao X, Tian L, Lu Y, Shu J-M, Lu C-J, Niu T, Kang B, Mao Y-Q, Liu F,Wen Y-J, Lei S, Luo F, Zhou L-Q, Peng F, Jiang Y, Liu J-Y, Zhou H, Wang Q-R, He Q-M, Xiao F, Lou Y-Y, Xie X-J, Li Q,Wu Y, Ding Z-Y,Hu B, Hu M, Zhang W. 2001. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci 98(20): 11545-11550.
27. Weich HA, Iberg N, Klagsbrun M, Folkman J. 1990. Expression of acidic and basic fibroblast growth factors in human and bovine vascular smooth muscle cells. Growth Factors 2(4):313-320.